Novo Nordisk acquires cardiovascular therapies developer
Novo Nordisk has acquired Cardior Pharmaeuticals for up to €1.025 billion, including an upfront payment and additional payments if certain milestones are achieved. Cardior is focused on the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart. Read More